Study on T-cell cancers after tisagenlecleucel treatment
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at people who developed a new T-cell cancer after receiving the CAR-T therapy tisagenlecleucel (Kymriah). Researchers want to understand these rare cancers by testing stored tumor samples. You may be eligible if you had tisagenlecleucel and were later diagnosed with a T-cell malignancy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received the CAR-T therapy tisagenlecleucel (Kymriah).
- You must have a confirmed diagnosis of a new T-cell cancer that happened after that therapy.
- A stored tissue, blood, or bone marrow sample from that T-cell cancer must be available for testing.
- You or your family must give permission (informed consent) for your samples to be used.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
This trial tests a new CAR T-cell therapy that targets CD22, after you've already received or been scheduled for a standard CD19-targeting CAR T-cell therapy (Kymriah). The goal is to see if giving a second type of CAR T cells can help when the first one doesn't work or the cancer returns.
This study looks at how safe and effective tisagenlecleucel is for people in Brazil who have certain B-cell blood cancers that came back or did not respond to treatment. You may be included if you already received tisagenlecleucel outside a research study and can consent to share your medical data.
This trial tests a type of immunotherapy called CAR-T cell therapy, which uses your own immune cells to fight lymphoma. It is for people who have already responded well to a second round of chemotherapy and are at high risk of the cancer coming back. The goal is to see if this treatment can keep the cancer away longer.
This trial offers testing of tumor samples for people who developed a new, different cancer after receiving a Bristol-Myers Squibb gene-modified cell therapy. The goal is to understand the genetics of that new cancer and see if it relates to the prior treatment.
This study looks at using tisagenlecleucel, a cell therapy, when the final product does not meet routine “commercial release” quality standards. It focuses on whether it can still be given safely and effectively to people with serious or life-threatening illness.
Hear when a new Secondary Malignancies of T-cell Origin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.